Research and Development

Our contribution to address patients’ unmet medical needs

DIATHEVA is passionate about the best science. We are a fully integrated company active in the research and development of novel biologic therapeutics in the oncology and infectious diseases areas. Our aspiration is to improve quality of life and bring health and a better future to patients, through highly innovative therapeutic solutions.

R&D Pipeline

Our portfolio of innovative therapeutic molecules

Program Indication Discovery Preclinical Phase I
A novel, first-in-class fully human recombinant antibody for the treatment of CD99 positive tumors.
Ewing’s sarcoma (EWS), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS)      
A novel fully human recombinant antibody and immune checkpoint inhibitor for the treatment of CEACAM1 positive tumors.
Solid tumors        
Anti-1.3 beta-glucans
A novel, first-in-class humanized antibody for the treatment of fungal infections, overcoming conventional drug resistance.
Fungal infections          

Let’s get in touch

If you wish to learn more about us, please fill the form!